Biota Of Australia Reaps Large Profits From Relenza Antiviral Royalties
This article was originally published in PharmAsia News
Executive Summary
Australia's Biota, the biotech that came up with the Relenza (zanamivir) antiviral marketed globally by U.K.-based GlaxoSmithKline, saw a doubling in royalties the past year. The near future looks even brighter for Biota, which reaped just over U.S.$31.5 million in profits, based primarily on the Relenza royalties. GSK plans by the end of the year to triple production of the drug as a major treatment for the widely expected H1N1 flu pandemic, so Biota anticipates a continuation of large royalties. (Click here for more